Gambol Pet Group Co., Ltd. (301498.SZ) engages in the research, development, production and sale of pet food products primarily for dogs and cats in China. The company offers a comprehensive portfolio of core products including dry food and wet food; staple foods featuring scientific nutritional formulas; snack series utilizing livestock, poultry and fish as primary raw materials; health care products such as freeze-dried lecithin and calcium lactate formulations; treats, chews and dental bones; and its flagship Myfoodie brand, which leads China's pet treat category and ranks prominently in dry food. Gambol operates three R&D centers and 18 factories in China plus two in Thailand, producing over 182,000 tons annually across 1,300 product varieties that it exports as a major OEM/ODM and private-label supplier to 33 countries in Europe, North America, Japan, South Korea and beyond, serving key clients like Walmart in the US. Founded in 2006 and headquartered in Liaocheng, Shandong Province, China, the company targets pet owners, retailers and global brands in the fast-growing pet nutrition sector with a focus on precision nutrition solutions for immunity, gut health, oral care, bone strength and life-stage needs. Recent developments include a strategic investment partnership with KKR to expand production capacity in China, Thailand, Europe and the US; its 2023 listing on the Shenzhen Stock Exchange GEM board; and a November 2025 announcement of a 950 million yuan investment in a new pet food project in New Zealand to further global operations.